Advancements in technology, particularly in data analytics and artificial intelligence, have the potential to revolutionize the drug approval process. These technologies can enhance the efficiency of data analysis, identify potential adverse effects more quickly, and improve patient selection for clinical trials. By leveraging big data, researchers and regulatory bodies can make more informed decisions, potentially shortening the time to approval.
